Latest News

The FDA will review Capricor Therapeutics' deramiocel for the treatment of Duchenne muscular dystrophy on July 29, 2026, ahead of the therapy's PDUFA target action date of August 22, 2026.

Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.

The ongoing phase 3 RELIEVE trial investigates the efficacy and safety of remibrutinib in patients with generalized myasthenia gravis who are on stable standard-of-care treatment.

A non-randomized controlled trial found that an MCT program added to standard rehabilitation significantly improved MoCA scores and reduced anxiety and depression at 4 and 12 weeks compared with standard care alone.

Johnson, who set the single-season NFL rushing record in 2009, went public with his diagnosis on Good Morning America, saying he hopes his story accelerates research and awareness of the disease.

A $2.5 million Michael J. Fox Foundation grant is funding 4 new sites for the NEULARK trial assessing NEU-411 as a potential disease-modifying therapy in genetically selected patients with early Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sex-based differences in neurology!

Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

Doris D. Wang, MD, PhD, Associate Professor of Neurological Surgery at UCSF, discusses a newly published adaptive deep brain stimulation system that adjusts in real time during walking and what it means for the future of Parkinson disease care.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]

REGENXBIO expects to resubmit the BLA for clemidsogene lanparvovec in Q3 2026 after the FDA confirmed existing CAMPSIITE data are sufficient for accelerated approval consideration.